Investor Presentaiton
Financial Results for Q4 FY2022
■Marketing Status of GEMTESAⓇ
Approx. 190,000 TRx in Q4 FY2022, which
is greater than our FY2022 forecast
(20% growth vs. Q3 FY2022)
+20%
■The market for overactive bladder (OAB) of
GEMTESAⓇ is over 400 billion yen/year (gross
conversion), and recently expanded by 8% annually*
Established broad health plan coverage (Percentage
of coverage obtained as of April 2023: total of
Medicare Part D lives was approx. 80%, total of
commercial lives was >70%)
193,661
161,156
133,949
101,140
65,858
48,299
26,715
6,800
Q1
Q2
Q3
Q4
Q1 Q2
Q3 Q4
FY2021 FY2021 FY2021 FY2021 FY2022 FY2022 FY2022 FY2022
■Phase 3 study results for OAB associated with
benign prostatic hyperplasia will be obtained in 1H
FY2023, and sNDA will be submitted in 2H FY2023
Number of prescriptions per quarter with GEMTESA®*
*Source IQVIA
*NSP sales as of end of Feb. 2023 and TRx as of end of Mar. 2023. Sales
for GEMTESAⓇ, MYRBETRIQ, TOVIAZ, and Generics for the 12 months
ended Feb. 2023 were $3.1B (130yen/$), which reflects a 8% growth vs
12 months ended Feb. 2022View entire presentation